look at this
Ridgeback Capital is a New-York based hedge fund firm established by Wayne Holman in 2006. Wayne Holman is a reputable investor who primarily specializes in health-care companies and is fearless in making big and concentrated bets, which usually turn out to be quite profitable. He is also a former SAC employee, serving as the portfolio manager at SAC’s subsidiary firm, Sigma Capital. Even more to that, Wayne Holman was possibly one of the biggest earners at SAC tailing the firm’s manager, Steven A. Cohen. As Mr. Holman is considered one of the most sound healthcare stars in the industry, it is quite appealing to take a look at his most recent healthcare acquisition. Thus, in this article we’ll thoroughly discuss Ridgeback Capital’s sizable investment in OncoSec Medical Incorporated (NASDAQ:ONCS).
OncoSec Medical Incorporated (NASDAQ:ONCS) is a hybrid device and gene therapy biotechnology company that is designing, developing, and commercializing proprietary medical approaches, mainly immunotherapy (i.e. treatments that use the body’s own immune system to help fight diseases, in this case advanced-stage skin cancer). The healthcare firm focuses primarily on three treatment-resistant fatal skin cancers: melanoma, Merkel cell lymphoma, and cutaneous T-cell lymphoma. Having said that, OncoSec has recently announced the enrollment of the first patient into OMS-I130, a Phase II clinical trial of ImmunoPulse™ IL-12. We are not going to analyze what this product is intended for and what it does, as only a handful of people can understand these technicalities and terminologies. However, it is evident that OncoSec has been quite successful in developing a treatment that is designed to help a high number of skin cancer patients in the U.S. and worldwide. It is then expected that the healthcare company will not only generate more revenues in the upcoming years, but will also hopefully save lives all around the world.
On June 15, OncoSec Medical announced that the company will join the Russell Microcap Index when the Russell indexes’ annual reconstitution is finalized, which will unquestionably increase the visibility of the company and its public awareness. Punit Dhillon, the president and CEO of OncoSec, believes that the inclusion in the index will assist the company in extending its shareholder base and advancing its clinical studies. The shares of OncoSec are currently trading at $7 a share and might keep rising as the company has been successful in advancing its clinical studies and in developing new products. Even more to that, a proxy for short-selling activity compiled by Markit suggests that there is little short-selling activity on this stock, which might be a clear sign that the market is confident in the medium- and long-term performance of OncoSec.
Even though OncoSec hasn’t generated any revenues so far, we’ll still briefly go through its financial results. The company posted a net loss of $1.19 per share for the nine-month period that ended on April 30, compared to a figure of a $0.96 per share loss reported for the same period a year ago. At the same time, OncoSec reported research and development expenses of $9.3 million for the nine months, compared to $3.9 million reported last year. Therefore, it is obvious that the company’s activities and development have started to increase, as OncoSec advances its product candidates further down their pipelines.
Hal Mintz‘s Sabby Management recently opened a large position of its own in OncoSec, consisting of 1.09 million shares, giving it a 7.36% stake in the company.